Company Overview and News
Stop missing out on important events!
MONTREAL, August 1, 2017 /PRNewswire/ -- Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced the completion of a US$55 million Series C financing. The round was led by Novo Holdings A/S, and included new investors Forbion Capital Partners and funds managed by Tekla Capital Management, with significant participation from Milestone's existing investors Domain Associates, Fonds de solidarité FTQ, BDC Capital, Pappas Capital, and GO Capital.
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii
ConvaTec Group Plc ("ConvaTec" or the "Company") is pleased to announce the proposed appointment of Mr Kasim Kutay as a Non-Executive Director of the Board.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER OF SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION.
ROSKILDE, Denmark--(BUSINESS WIRE)--Sonion today announced the appointment of Jesper Ahlmann Funding Andersen as the President & CEO of the Sonion Group. Jesper replaces Jørn Mørkeberg Nielsen who was President & CEO of Sonion until the end of 2016.
LINKÖPING, Sweden--(BUSINESS WIRE)--Swedish-based digital health company AMRA has announced today a $9 million funding round co-led by US-based Pfizer Venture Investments and leading Nordic VC Novo Seeds. Industrifonden, another leading Nordic VC and current AMRA investor, also participated, making this their second AMRA investment.
Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financing round. The Company has also acquired global rights to a novel technology platform, Esterase Sensitive Motif (ESM), from Chroma Therapeutics Limited (Oxford, UK) together with discovery stage therapeutic assets.